Recent investigations have converged on the overlap of GLP-1|GIP|glucagon receptor stimulant therapies and dopaminergic signaling. While GLP activators are commonly employed for treating type 2 T2DM, their emerging impacts on reward circuits, specifically governed by dopamine systems, are receiving significant focus. This article provides a concise